Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs;Dyskinésies tardives induites par les antipsychotiques: Données actuelles sur leur prévention et prise en charge

Encephale

Volumn 42, Issue 3, 2016, Pages 248-254

  Seigneurie, A S ^a   Sauvanaud, F ^a   Limosin, F ^a,b,c  

^a Paris Descartes University   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE PSYCHIATRIE ET NEUROSCIENCES   (France)

Author keywords

Antipsychotic drugs; Iatrogenic disease; Neuroleptics; Tardive dyskinesia; Tardive dystonia

Indexed keywords

AMANTADINE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; GABAERGIC RECEPTOR AFFECTING AGENT; NEUROLEPTIC AGENT; TETRABENAZINE;

AGE; ALCOHOLISM; ALZHEIMER DISEASE; BIPOLAR DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; COCAINE DEPENDENCE; DIFFERENTIAL DIAGNOSIS; ELECTROCONVULSIVE THERAPY; GENDER; HUMAN; HUNTINGTON CHOREA; METABOLIC DISORDER; NERVE CELL DIFFERENTIATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TRANSCRANIAL MAGNETIC STIMULATION; WILSON DISEASE; COMPLICATION; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; HUMANS; PSYCHOTIC DISORDERS; TARDIVE DYSKINESIA;

EID: 84959119055     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.encep.2015.12.021     Document Type: Article

References (50)

1. Chowdhury NI, Remington G, Kennedy JL. Genetics of antipsychotic-induced side effects and agranulocytosis. Curr Psychiatry Rep 2011;13(2):156-65.
2. Alimi M. Traitement des dyskinésies tardives aux neuroleptiques: une revue systématique de la littérature. Tours: Université Franç ois Rabelais; 2011 [Thèse].
3. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151-6.
4. e éd. Paris: Garnier-Delamare; 2003.
5. Viallet F, Vercueil L, Gayraud D, et al. Mouvements anormaux secondaires (dystonies, myoclonies, tremblements, dyskinésies). EMC Neurologie; 2005. p. 430-52.
6. Bhimani MM. Respiratory dyskinesia-an under-recognized side-effect of neuroleptic medications. J Pak Med Assoc 2011;61(9):930.
7. Chaumartin N, Monville M, Lachaux B. Une ou des dysphagies lors d'un traitement par neuroleptiques? Encéphale 2012;38(4):351-5.
8. http://www.theriaque.org.
9. Woerner MG, Correll CU, Alvir JM, et al. Incidence of tardive dyskinesia with risperidone or olanzapine in the elderly: results from a 2-year, prospective study in antipsychotic-naïve patients. Neuropsychopharmacology 2011;36:1738-46.
10. Yassa R, Nair V. Incidence of tardive dyskinesia in an outpatient population. Psychosomatics 1984;25(6):479-81.
11. Kane JM, Woerner M, Liebermann J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(4):57.
12. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in olderpatients. A prospective longitudinal study of 266 outpatients. Arch Gen Psy-chiatry 1995;52(9):756-65.
13. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003;53(12):1142-5.
14. Mink JW. The basal ganglia and involuntary movements: impaired inhibition of competing motor patterns. Arch Neurol 2003;60(10):1365.
15. Marchand WR, Dilda V. New models of frontal-subcortical skeletomotor circuit pathology in tardive dyskinesia. Neuroscientist 2006;12(3):186-98.
16. Tan YL, Zhou DF, Zhang XY. Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2005;74(2):263-70.
17. Woerner MG, Alvir J, Saltz BL, et al. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. Am J Psychiatry 1998;155:1521-8.
18. Jeste DV, Okamoto A, Napolitano J, et al. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone. Am J Psychiatry 2000;157:1150-5.
19. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000;61(4):15-20.
20. Llorca PM, Chereau I, Bayle FJ, et al. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002;17(3):129-38.
21. Boks MP, Liddle PF, Burgerhof JG, et al. Neurological soft signs discriminating mood disorders from first episode schizophrenia. Acta Psychiatr Scand 2004;110(1):29-35.
22. Miller DD, Caroff SN, Davis SM, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008;193:279-88.
23. Tenback DE, Van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Mov Disord 2009;24(16):2309-15.
24. Saltz BL, Woerner MGx, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991;266(17):2402-6.
25. McCreadie RG, Thara R, Padmavati R, et al. Structural brain differences between never-treated patients with schizophrenia, with and without dyskinesia, and normal control subjects: a magnetic resonance imaging study. Arch Gen Psychiatry 2002;59(4):332-6.
26. Chatterjee A, Chakos M, Koreen A, et al. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am J Psychiatry 1995;152(12):1724-9.
27. Ismail B, Cantor-Graae E, McNeil TF. Neurodevelopmental origins of tardive like dyskinesia in schizophrenia patients and their siblings. Schizophr Bull 2001;27(4):629-41.
28. Müller DJ, Shinkai T, De Luca V, et al. Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004;4(2):77-87.
29. Casey DE. Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65:25-8.
30. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172(13):1703-11.
31. Van Harten PN, Hoek HW, Matroos GE, et al. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curacao extrapyramidal syndromes study V. J Clin Psychiatry 2006;67(12):1920-7.
32. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007;27(2):159-69.
33. Van Harten PN, Tenback DE. Tardive dyskinesia: clinical presentation and treatment. Int Rev Neurobiol 2011;98:187-210.
34. Jeste DV, Lohr JB, Clark K, et al. Pharmacological treatments of tardive dyskinesia in the 1980s. J Clin Psychopharmacol 1988;8(4):38S-48S.
35. Fernandez HH, Friedman JH. Classification and treatment of tardive syndromes. Neurologist 2003;9:16-27.
36. Soares-Weiser K, Rathbone J. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. Cochrane Database Syst Rev 2006;25(1) [CD000459].
37. Chan HY, Chiang SC, Chang CJ, et al. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia. J Clin Psychiatry 2010;71(9):1226-33.
38. Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatry 2013;6:439-51.
39. Kenney C, Hunter C, Mejia N, et al. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 2006;29(5): 259-64.
40. Soares-Weiser K, Maayan N, McGrath J. Vitamin E for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;16(2) [CD000209].
41. Tammenmaa IA, Sailas E, McGrath JJ, et al. Systematic review of cholinergic drugs for neuroleptic-induced tardive dyskinesia: a meta-analysis of randomized controlled trials. Prog Neuropsychopharmacol Biol Psychiatry 2004;28(7):1099-107.
42. Bhoopathi PS, Soares-Weiser K. Benzodiazepines for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2006;19(3) [CD000205].
43. Alabed S, Latifeh Y, Mohammad HA, et al. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2011;13(4) [CD000203].
44. Pappa S, Tsouli S, Apostolou G, et al. Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol 2010;33:271-5.
45. Yasui-Furukori N, Kikuchi A, Katagai H, et al. The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study. Neuropsychiatr Dis Treat 2014;10:1209.
46. Soares-Weiser V, Joy C. Miscellaneous treatments for neuroleptic-induced tardive dyskinesia. Cochrane Database Syst Rev 2003;2 [CD000208].
47. Edwards J, Talelli P, Rothwell C. Clinical applications of transcranial magnetic stimulation in patients with movement disorders. Lancet Neurol 2008;7(9):827-40.
48. Damier P, Thobois S, Witjas T, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry 2007;64: 170-6.
49. Sako W, Goto S, Shimazu H, et al. Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Mov Disord 2008;23: 1929-31.
50. Gruber D, Trottenberg T, Kivi A, et al. Long-term effects of pallidal deep brain stimulation in tardive dystonia. Neurology 2009;73:53-8.